ハンチントン病におけるハンチントンの集積と毒性
1Medical and Molecular Genetics, GKT School of Medicine, King's College London, Guy's Hospital, SE1 9RT, London, UK. gillian.bates@kcl.ac.uk <gillian.bates@kcl.ac.uk>
Lancet (London, England)
|May 16, 2003
まとめ
ハンチントン病は,有毒なポリグルタミン (polyQ) アグリゲートに関連しています. 彼らの形成を阻害することは,この神経変性障害の治療戦略として有望であることが示されています.
科学分野:
- 神経科学は神経科学である.
- 遺伝学 遺伝学とは
- 分子生物学は分子生物学である.
背景:
- ハンチントン病 (HD) と関連する疾患は,ハンチントンチン遺伝子のCAG/ポリグルタミン (polyQ) 繰り返し拡張から生じる.
- 変異したハンティングチンのタンパク質は,これらの神経変性疾患の特徴である集合体を形成します.
- 疾患の病原性におけるポリQ集積の正確な役割は,検出の課題によって複雑化し,議論の余地があります.
研究 の 目的:
- プリフォームされたポリグルタミン (polyQ) アグレガートの毒性を調査する.
- ハンチントン病におけるポリQ集積を標的とした治療の可能性を調査する.
主な方法:
- 陽氏とその同僚による研究 (2002年) を利用し,核誘導型ポリQ集積物の毒性を実証した.
- ハンチントン病のマウスモデルにおける集積形成の薬理学的阻害に関するサンチェス氏および同僚の研究 (2003年) を参照.
主要な成果:
- プリフォームされたポリグルタミン (polyQ) アグレガートは,細胞核に局所化すると非常に有毒である.
- ポリQ集積形成の薬理学的阻害は,ハンティントン病のマウスモデルで有益な効果をもたらしました.
結論:
- ポリQアグレガートの確立された毒性は,ハンチントン病の有効な治療目標として,アグレゲーション阻害を検証しています.
- ポリQ積層の形成と構造に関するさらなる研究が必要である.
- アグリゲーション阻害剤に対する高通量スクリーニングと早期のin-vivo研究は,将来のハンチントン病の治療法の開発に有望である.
関連する概念動画
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...


